41 results on '"Carrascosa, José Manuel"'
Search Results
2. Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
- Author
-
Torres, Tiago, Sohrt Petersen, Anne, Ivens, Ulla, Bosch Vilaro, Albert, Stinson, John, and Carrascosa, José Manuel
- Published
- 2024
- Full Text
- View/download PDF
3. Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review
- Author
-
Torres, Tiago, Galván, Jordi, Crutchley, Nigel, Praestegaard, Morten, Iversen, Lars, Gisondi, Paolo, Carrascosa, José Manuel, Halioua, Bruno, Bewley, Anthony, and Pinter, Andreas
- Published
- 2023
- Full Text
- View/download PDF
4. Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment
- Author
-
Rivera-Díaz, Raquel, Daudén, Esteban, Carrascosa, José Manuel, Cueva, Pablo de la, and Puig, Luis
- Published
- 2023
- Full Text
- View/download PDF
5. Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)
- Author
-
Daudén, Esteban, de la Cueva, Pablo, Salgado-Boquete, Laura, Llamas-Velasco, Mar, Fonseca, Eduardo, Pau-Charles, Ignasi, Asensio, David, Guilà, Meritxell, and Carrascosa, José Manuel
- Published
- 2023
- Full Text
- View/download PDF
6. Knowledge, perceptions, attitude, barriers and facilitators of biosimilars use across specialty physicians and hospital pharmacists: A national survey
- Author
-
Marín-Jiménez, Ignacio, Carrascosa, José Manuel, Guigini, Marcelo Alejandro, and Monte-Boquet, Emilio
- Published
- 2021
- Full Text
- View/download PDF
7. The Role of Photoprotection in Optimizing the Treatment of Atopic Dermatitis
- Author
-
Piquero-Casals, Jaime, Carrascosa, José Manuel, Morgado-Carrasco, Daniel, Narda, Mridvika, Trullas, Carles, Granger, Corinne, and Fabbrocini, Gabriella
- Published
- 2021
- Full Text
- View/download PDF
8. Matching-Adjusted Indirect Comparison of the Efficacy of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis Beyond Week 16
- Author
-
Torres, Tiago, primary, Sohrt Petersen, Anne, additional, Rosso, Aldana Mariela, additional, Moreira Taveira, Christian, additional, and Carrascosa, José Manuel, additional
- Published
- 2024
- Full Text
- View/download PDF
9. Adhesion Molecules Associated with Female Genital Tract Infection
- Author
-
Qualai, Jamal, Cantero, Jon, Li, Lin-Xi, Carrascosa, José Manuel, Cabré, Eduard, Dern, Olga, Sumoy, Lauro, Requena, Gerard, McSorley, Stephen J, and Genescà, Meritxell
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Immunology ,Biotechnology ,HIV/AIDS ,Infectious Diseases ,Immunization ,2.1 Biological and endogenous factors ,Aetiology ,Inflammatory and immune system ,Infection ,Adult ,Animals ,CD11c Antigen ,Cell Adhesion Molecules ,Chlamydia Infections ,Chlamydia muridarum ,Disease Models ,Animal ,Female ,Gardnerella vaginalis ,HeLa Cells ,Humans ,Integrin alpha4beta1 ,Mice ,Receptors ,CCR2 ,Receptors ,CCR5 ,Receptors ,CCR6 ,T-Lymphocytes ,Vaginosis ,Bacterial ,Young Adult ,Hela Cells ,General Science & Technology - Abstract
Efforts to develop vaccines that can elicit mucosal immune responses in the female genital tract against sexually transmitted infections have been hampered by an inability to measure immune responses in these tissues. The differential expression of adhesion molecules is known to confer site-dependent homing of circulating effector T cells to mucosal tissues. Specific homing molecules have been defined that can be measured in blood as surrogate markers of local immunity (e.g. α4β7 for gut). Here we analyzed the expression pattern of adhesion molecules by circulating effector T cells following mucosal infection of the female genital tract in mice and during a symptomatic episode of vaginosis in women. While CCR2, CCR5, CXCR6 and CD11c were preferentially expressed in a mouse model of Chlamydia infection, only CCR5 and CD11c were clearly expressed by effector T cells during bacterial vaginosis in women. Other homing molecules previously suggested as required for homing to the genital mucosa such as α4β1 and α4β7 were also differentially expressed in these patients. However, CD11c expression, an integrin chain rarely analyzed in the context of T cell immunity, was the most consistently elevated in all activated effector CD8+ T cell subsets analyzed. This molecule was also induced after systemic infection in mice, suggesting that CD11c is not exclusive of genital tract infection. Still, its increase in response to genital tract disorders may represent a novel surrogate marker of mucosal immunity in women, and warrants further exploration for diagnostic and therapeutic purposes.
- Published
- 2016
10. Spaghetti Technique Versus Wide Local Excision for Lentigo Maligna Affecting the Head and Neck Regions: Surgical Outcome and Descriptive Analysis of 79 Cases From a Single Practice Cohort
- Author
-
Martinez-Molina, Manel, primary, Richarz, Nina, additional, Jaka, Ane, additional, Bassas-Vila, Juli, additional, Mora-Fernández, Verónica, additional, Quer Pi-Sunyer, Ariadna, additional, Podlipnik, Sebastian, additional, Carrascosa, José Manuel, additional, and Boada, Aram, additional
- Published
- 2023
- Full Text
- View/download PDF
11. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry
- Author
-
Pérez Zafrilla, Beatriz, Muñoz-Santos, Carlos, Mendiola-Fernández, Victoria, Sánchez Roldán, Cristina, Ruiz-Genao, Diana, Echeverría, Begoña, Galiano Mejías, Sagrario, Dávila-Seijo, Paula, Dauden, Esteban, Descalzo, M.A., Carretero, Gregorio, Carrascosa, José-Manuel, Vanaclocha, Francisco, Gómez-García, Francisco-José, De la Cueva-Dobao, Pablo, Herrera-Ceballos, Enrique, Belinchón, Isabel, López-Estebaranz, José-Luis, Alsina, Merce, Sánchez-Carazo, José-Luis, Ferrán, Marta, Torrado, Rosa, Ferrandiz, Carlos, Rivera, Raquel, Llamas, Mar, Jiménez-Puya, Rafael, and García-Doval, Ignacio
- Published
- 2017
- Full Text
- View/download PDF
12. Genetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis
- Author
-
Consuegra-Fernández, Marta, Julià, Marc, Martínez-Florensa, Mario, Aranda, Fernando, Català, Cristina, Armiger-Borràs, Noelia, Arias, María-Teresa, Santiago, Francisca, Guilabert, Antonio, Esteve, Anna, Muñoz, Carlos, Ferrándiz, Carlos, Carrascosa, José- Manuel, Pedrosa, Edurne, Romaní, Jorge, Alsina, Mercè, Mascaró-Galy, José- Manuel, and Lozano, Francisco
- Published
- 2018
- Full Text
- View/download PDF
13. The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease
- Author
-
Olveira, Antonio, primary, Augustin, Salvador, additional, Benlloch, Salvador, additional, Ampuero, Javier, additional, Suárez-Pérez, Jorge Alonso, additional, Armesto, Susana, additional, Vilarrasa, Eva, additional, Belinchón-Romero, Isabel, additional, Herranz, Pedro, additional, Crespo, Javier, additional, Guimerá, Francisco, additional, Gómez-Labrador, Lara, additional, Martín, Víctor, additional, and Carrascosa, José Manuel, additional
- Published
- 2023
- Full Text
- View/download PDF
14. No impact of disease duration on response to tildrakizumab treatment among patients with moderate‐to‐severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies.
- Author
-
Griss, Johannes, Ratzinger, Gudrun, Maul, Julia‐Tatjana, Weger, Wolfgang, Thaçi, Diamant, Carrascosa, José Manuel, and Jonak, Constanze
- Published
- 2023
- Full Text
- View/download PDF
15. The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease
- Author
-
Olveira, Antonio, Augustin Recio, Salvador, Benlloch, Salvador, Ampuero, Javier, Suárez-Pérez, Jorge Alonso, Armesto, Susana, Vilarrasa-Rull, Eva, Belinchón, Isabel, Herranz, Pedro, Crespo García, Javier, Guimerá, Francisco, Gómez-Labrador, Lara, Martín, Víctor, Carrascosa, José Manuel, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Olveira A] Department of Digestive Diseases, La Paz University Hospital, Madrid, Spain. [Augustin S] Unitat Hepàtica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Benlloch S] Department of Digestive Diseases, Arnau de Vilanova Hospital, Centro Biomédico en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Valencia, Spain. [Ampuero J] Department of Digestive Diseases, Virgen del Rocío University Hospital, Institute of Biomedicine of Sevilla (IBIS), Department of Medicine, University of Sevilla, Centro Biomédico en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Sevilla, Spain. [Suárez-Pérez JA] Department of Dermatology, Virgen de la Victoria University Hospital, Málaga, Spain. [Armesto S] Department of Dermatology, Marqués de Valdecilla University Hospital, Santander, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Psoriasi ,enfermedades del sistema digestivo::enfermedades hepáticas::hígado graso::esteatosis hepática no alcohólica [ENFERMEDADES] ,Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Cytokines::Interleukins::Interleukin-17 [CHEMICALS AND DRUGS] ,Digestive System Diseases::Liver Diseases::Fatty Liver::Non-alcoholic Fatty Liver Disease [DISEASES] ,Paleontology ,MAFLD ,Interleucines ,Other subheadings::Other subheadings::/metabolism [Other subheadings] ,Esteatosi hepàtica - Patogènesi ,General Biochemistry, Genetics and Molecular Biology ,Fetge - Metabolisme ,IL-17 ,Space and Planetary Science ,Skin and Connective Tissue Diseases::Skin Diseases::Skin Diseases, Papulosquamous::Psoriasis [DISEASES] ,Metabolic-associated fatty liver disease ,IL-17A ,aminoácidos, péptidos y proteínas::péptidos::péptidos y proteínas de señalización intercelular::citocinas::interleucinas::interleucina-17 [COMPUESTOS QUÍMICOS Y DROGAS] ,Psoriasis ,enfermedades de la piel y tejido conjuntivo::enfermedades de la piel::enfermedades cutáneas papuloescamosas::psoriasis [ENFERMEDADES] ,Ecology, Evolution, Behavior and Systematics ,Otros calificadores::Otros calificadores::/metabolismo [Otros calificadores] - Abstract
IL-17; Enfermedad del hígado graso asociada al metabolismo; Psoriasis IL-17; Metabolic-associated fatty liver disease; Psoriasis IL-17; Malaltia del fetge gras associada al metabolisme; Psoriasi Interleukin 17 (IL-17) is an effector cytokine that plays a key role in the pathogenesis of both psoriasis and metabolic-associated fatty liver disease (MAFLD), a condition that is more prevalent and severe in patients with psoriasis. In liver inflammation, IL-17 is mainly produced by CD4+ T (TH17) and CD8+ T cells (Tc17), although numerous other cells (macrophages, natural killer cells, neutrophils and Tγδ cells) also contribute to the production of IL-17. In hepatocytes, IL-17 mediates systemic inflammation and the recruitment of inflammatory cells to the liver, and it is also implicated in the development of fibrosis and insulin resistance. IL-17 levels have been correlated with progression from MAFLD to steatohepatitis, cirrhosis, and even hepatocellular carcinoma. Clinical trials have shown that inhibiting IL-17A in patients with psoriasis could potentially contribute to the improvement of metabolic and liver parameters. A better understanding of the key factors involved in the pathogenesis of these chronic inflammatory processes could potentially lead to more efficient treatment for both psoriasis and MAFLD, and help to develop holistic strategies to improve the management of these patients. Financial support for the expert meetings and manuscript preparation were provided by Novartis Farmacéutica S.A.
- Published
- 2023
16. The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain
- Author
-
Maravilla-Herrera, Paulina, Merino, María, Alfonso Zamora, Santiago, Balea Filgueiras, Jesús, Carrascosa, José Manuel, Delgado Sánchez, Olga, Dolz Sinisterra, Francisco, García-Ruiz, Antonio, Herranz Pinto, Pedro, Manfredi, Antonio, Martínez Olmos, José, Morales de los Ríos Luna, Paloma, Puig Sanz, Lluís, Ros, Sandra, Hidalgo, Álvaro, and Universitat Autònoma de Barcelona
- Subjects
Quality of life ,Psoriasis Area and Severity Index (PASI) ,Public Health, Environmental and Occupational Health ,Activities of daily living ,Psoriasis ,Social return ,Out-of-pocket (OOP) expenses ,Socioeconomic impact - Abstract
IntroductionPsoriasis is a chronic disease involving the skin, which significantly impacts the quality of life. Disease severity and treatment efficacy (i.e., response) are assessed through the Psoriasis Area and Severity Index (PASI). A PASI 75 response, i.e., an improvement of at least 75% with respect to the baseline PASI score, has traditionally been used as a therapeutic benchmark in clinical trials. Therapeutic advances have made PASI 90 or PASI 100 responses possible in most patients treated with some biologics. A greater response may generate social value beyond clinical outcomes that would benefit both patients and society.MethodsA 1-year economic model was applied to estimate the impact of having a PASI 75, PASI 90, or PASI 100 response in four areas of analysis (quality of life, activities of daily living, work productivity, and out-of-pocket expenditures) and the social value of having a PASI 90 or PASI 100 response in comparison with a PASI 75 response. A mixed-methods approach based on the scientific literature, a focus group with patient, and an advisory committee with psoriasis stakeholders was used. The model included three different scenarios: having a PASI 90 vs a PASI 75 response; a PASI 100 vs a PASI 90 response; and a PASI 100 vs a PASI 75 response. A sensitivity analysis was included.ResultsThe annual economic impact per patient with moderate-to-severe plaque psoriasis having a PASI 75 response was estimated at Ł 6,139, mainly related to labour productivity losses and quality of life reductions. Having a PASI 90 or a PASI 100 response would reduce this impact to €3,956 or €1,353, respectively. Accordingly, the social value of having a PASI 90 instead of a PASI 75 response was estimated at €2,183, and €4,786 with a PASI 100 response.DiscussionA PASI 90 or PASI 100 response would have a lower economic impact and a greater social value than a PASI 75 response for patients with moderate-to-severe plaque psoriasis.
- Published
- 2023
17. Drug Survival of Interleukin (IL)‐17 and IL‐23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‐country, Multicentric Cohort Study
- Author
-
Torres, Tiago, Puig, Lui, Vender, Ron, Yeung, Jensen, Carrascosa, José-Manuel, Piaserico, Stefano, Gisondi, Paolo, Lynde, Charle, Ferreira, Paulo, Bastos, Pedro Mende, Dauden, Esteban, Leite, Luiz, Valerio, Joana, Del Alcázar-Viladomiu, Elena, Rull, Eva Vilarrasa, Llamas-Velasco, Mar, Pirro, Federico, Messina, Francesco, Bruni, Manfredo, Licata, Gaetano, Ricceri, Federica, Nidegger, Alessia, Hugo, Jan, Mufti, Asfandyar, Daponte, Athina-Ioanna, Teixeira, Laetitia, Balato, Anna, Romanelli, Marco, Prignano, Francesca, Gkalpakiotis, Spyridon, Conrad, Curdin, Lazaridou, Elizabeth, Rompoti, Natalia, Papoutsaki, Marina, Nogueira, Miguel, Chiricozzi, Andrea, Chiricozzi, Andrea (ORCID:0000-0002-6739-0387), Torres, Tiago, Puig, Lui, Vender, Ron, Yeung, Jensen, Carrascosa, José-Manuel, Piaserico, Stefano, Gisondi, Paolo, Lynde, Charle, Ferreira, Paulo, Bastos, Pedro Mende, Dauden, Esteban, Leite, Luiz, Valerio, Joana, Del Alcázar-Viladomiu, Elena, Rull, Eva Vilarrasa, Llamas-Velasco, Mar, Pirro, Federico, Messina, Francesco, Bruni, Manfredo, Licata, Gaetano, Ricceri, Federica, Nidegger, Alessia, Hugo, Jan, Mufti, Asfandyar, Daponte, Athina-Ioanna, Teixeira, Laetitia, Balato, Anna, Romanelli, Marco, Prignano, Francesca, Gkalpakiotis, Spyridon, Conrad, Curdin, Lazaridou, Elizabeth, Rompoti, Natalia, Papoutsaki, Marina, Nogueira, Miguel, Chiricozzi, Andrea, and Chiricozzi, Andrea (ORCID:0000-0002-6739-0387)
- Abstract
Background: Drug survival, defined as the length of time from initiation to discontinuation of a given therapy, allows comparisons between drugs, helps to predict patient's likelihood of remaining on a specific treatment, and achieving the best decision for each patient in daily clinical practice. Objective: The aim of this study was to provide data on drug survival of secukinumab, ixekizumab, brodalumab, guselkumab, tildrakizumab, and risankizumab in a large international cohort, and to identify clinical predictors that might have an impact on the drug survival of these drugs. Methods: This was a retrospective, multicentric, multi-country study that provides data of adult patients with moderate to severe psoriasis who started treatment with an interleukin (IL)-17 or IL-23 inhibitor between 1 February 2015 and 31 October 2021. Data were collected from 19 distinct hospital and non-hospital-based dermatology centers from Canada, Czech Republic, Italy, Greece, Portugal, Spain, and Switzerland. Kaplan-Meier estimator and proportional hazard Cox regression models were used for drug survival analysis. Results: A total of 4866 treatment courses (4178 patients)-overall time of exposure of 9500 patient-years-were included in this study, with 3164 corresponding to an IL-17 inhibitor (secukinumab, ixekizumab, brodalumab) and 1702 corresponding to an IL-23 inhibitor (guselkumab, risankizumab, tildrakizumab). IL-23 inhibitors had the highest drug survival rates during the entire study period. After 24 months of treatment, the cumulative probabilities of drug survival were 0.92 (95% confidence interval [CI] 0.89-0.95) for risankizumab, 0.90 (95% CI 0.88-0.92) for guselkumab, 0.80 (95% CI 0.76-0.84) for brodalumab, 0.79 (95% CI 0.76-0.82) for ixekizumab, and 0.75 (95% CI 0.73-0.77) for secukinumab. At 36 months, only guselkumab [0.88 (95% CI 0.85-0.91)], ixekizumab [0.73 (95% CI 0.70-0.76)], and secukinumab [0.67 (95% CI 0.65-0.70)] had more than 40 patients at risk of drug discon
- Published
- 2022
18. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
- Author
-
del Alcázar Viladomiu, Elena, López-Ferrer, Anna, Martínez-Doménech, Álvaro, Ruiz-Villaverde, R., Llamas-Velasco, Mar, Rocamora, V., Julià, M., Notario, J., Fernández-Freire, L. R., Sahuquillo-Torralba, A., Vidal, D., Rivera, Raquel, Carretero, G., Mateu, A., de la Cueva, Pablo, Carrascosa, José Manuel, and Universitat Autònoma de Barcelona
- Subjects
Adult ,medicine.medical_specialty ,real-world ,Multivariate analysis ,Dermatology ,Antibodies, Monoclonal, Humanized ,Severity of Illness Index ,Psoriasis Area and Severity Index ,Internal medicine ,Psoriasis ,medicine ,Humans ,Adverse effect ,Retrospective Studies ,business.industry ,General Medicine ,medicine.disease ,Response to treatment ,humanities ,Clinical trial ,guselkumab ,Guselkumab ,Treatment Outcome ,Observational study ,business - Abstract
Altres ajuts: acords transformatius de la UAB Data on the effectiveness and safety of a drug in real-world clinical practice complement the evidence from clinical trials, which are carried out in a different setting. Little has been published on the effectiveness and safety of guselkumab in the treatment of psoriasis in clinical practice. The ojective of this study was to assess the effectiveness and safety of guselkumab at 24 weeks in patients with moderate to severe plaque psoriasis in routine clinical practice. A retrospective, multicentre study of adult patients with moderate to severe plaque psoriasis treated with guselkumab for at least 24 weeks was carried out in Spain. We studied 343 patients, 249 of whom were followed for 24 weeks. By week 24, the mean (SD) psoriasis area severity index (PASI) had decreased from 11.1 (7.3) to 1.7 (2.8) (−9.3; [−10.2;-8.4]), 85.9% of the patients had achieved PASI score of 4 or less and 77.9% a PASI score of 2 or less. In terms of relative PASI response, 59.4% of the patients achieved a PASI-90 response and 49.0% a PASI-100 response. On multivariate analysis, two factors reduced the probability of a PASI of 2 or less at 24 weeks: a BMI ≥30 (OR, 0.44; 95% CI, 0.22-0.88) and a greater previous exposure to biologic therapy (OR, 0.69; 95% CI, [0.56-0.84]). Adverse events were rare (9.9%) and led to withdrawal from treatment in only nine patients (2.6%) by the end of the follow-up period. The results of this study confirm the high efficacy and safety of guselkumab indicated by the clinical trial data. In clinical practice, the absolute PASI score appears to be a better marker of response to treatment than the relative value.
- Published
- 2022
19. A New Classification of the Severity of Psoriasis: What’s Moderate Psoriasis?
- Author
-
Salgado-Boquete, Laura, primary, Carrascosa, José Manuel, additional, Llamas-Velasco, Mar, additional, Ruiz-Villaverde, Ricardo, additional, de la Cueva, Pablo, additional, and Belinchón, Isabel, additional
- Published
- 2021
- Full Text
- View/download PDF
20. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks : A retrospective, observational, multicentre study by the Spanish Psoriasis Group
- Author
-
del Alcázar Viladomiu, Elena, López-Ferrer, Anna, Martínez-Doménech, Álvaro, Ruiz-Villaverde, R., Llamas-Velasco, Mar, Rocamora, V., Julià, M., Notario, J., Fernández-Freire, L.R., Sahuquillo-Torralba, A., Vidal, D., Rivera, Raquel, Carretero, G., Mateu, A., de la Cueva, P., Carrascosa, José Manuel, Universitat Autònoma de Barcelona, del Alcázar Viladomiu, Elena, López-Ferrer, Anna, Martínez-Doménech, Álvaro, Ruiz-Villaverde, R., Llamas-Velasco, Mar, Rocamora, V., Julià, M., Notario, J., Fernández-Freire, L.R., Sahuquillo-Torralba, A., Vidal, D., Rivera, Raquel, Carretero, G., Mateu, A., de la Cueva, P., Carrascosa, José Manuel, and Universitat Autònoma de Barcelona
- Abstract
Altres ajuts: Acord transformatiu CRUE-CSIC, Data on the effectiveness and safety of a drug in real-world clinical practice complement the evidence from clinical trials, which are carried out in a different setting. Little has been published on the effectiveness and safety of guselkumab in the treatment of psoriasis in clinical practice. The ojective of this study was to assess the effectiveness and safety of guselkumab at 24 weeks in patients with moderate to severe plaque psoriasis in routine clinical practice. A retrospective, multicentre study of adult patients with moderate to severe plaque psoriasis treated with guselkumab for at least 24 weeks was carried out in Spain. We studied 343 patients, 249 of whom were followed for 24 weeks. By week 24, the mean (SD) psoriasis area severity index (PASI) had decreased from 11.1 (7.3) to 1.7 (2.8) (−9.3; [−10.2;-8.4]), 85.9% of the patients had achieved PASI score of 4 or less and 77.9% a PASI score of 2 or less. In terms of relative PASI response, 59.4% of the patients achieved a PASI-90 response and 49.0% a PASI-100 response. On multivariate analysis, two factors reduced the probability of a PASI of 2 or less at 24 weeks: a BMI ≥30 (OR, 0.44; 95% CI, 0.22-0.88) and a greater previous exposure to biologic therapy (OR, 0.69; 95% CI, [0.56-0.84]). Adverse events were rare (9.9%) and led to withdrawal from treatment in only nine patients (2.6%) by the end of the follow-up period. The results of this study confirm the high efficacy and safety of guselkumab indicated by the clinical trial data. In clinical practice, the absolute PASI score appears to be a better marker of response to treatment than the relative value.
- Published
- 2021
21. Dermatitis atópica
- Author
-
Armario Hita, J. C., Galán Gutiérrez, Manuel, Carrascosa, José Manuel, Armario Hita, J. C., Galán Gutiérrez, Manuel, and Carrascosa, José Manuel
- Abstract
Atopic dermatitis (AD) is a chronic inflammatory disease with a complex pathophysiology in which genetic, immunological and environmental factors are involved. Its pathophysiology implies a structural and functional alteration of the skin barrier and an alteration of the Th2 (T-helper cell type 2)-pattern-immune response. This alterations produce an inflammatory response. The typical symptoms are cutaneous xerosis, intense itching and eczema. However, its phenotype is very heterogene ous and varies with age. To assess its severity, several scales have been described, of which the most used are EASI (Eczema Area and Severity Index) and SCORAD (Scoring Atopic Dermatitis). AD can be associated with immuno-allergic comorbidities, especially asthma, rhinitis and conjunctivitis. It is also related to a higher frequency of depression and anxiety. AD has several treatment options including topical treatments (corticosteroids, tacrolimus, pimecrolimus, chrysoborol), physical treatments (phototherapy), systemic treatments (corticosteroids, cyclosporine, methotrexate, azathioprine, mycophenolate mofetil), biological therapies (dupilumab, tralokinumab, lebrikizumab, nemolizumab) or JAK (Janus kinase) inhibitors (baricitinib, upadacitinib, abrocitinib)., La dermatitis atópica (DA) es una enfermedad inflama toria crónica de fisiopatología compleja, en la que intervienen factores genéticos, inmunitarios y ambientales. En su fisiopatología, participan una alteración estructural y funcional de la barrera cutánea y una alteración de la respuesta inmunitaria de patrón Th2 (linfocitos T colaboradores de tipo 2), como consecuencia de lo cual se producen sus manifestaciones inflamatorias. La clínica típica es la coexistencia de xerosis cutánea, prurito intenso y eccema. Sin embargo, su fenotipo es muy heterogéneo y varía con la edad. Para valorar su gravedad, se han descrito varias escalas, de las que las más utilizadas son el índice de intensidad y gravedad del eccema o EASI (Eczema Area and Severity Index) y la puntuación para medir la gravedad y extensión de las lesiones de la DA SCORAD (Scoring Atopic Dermatitis). La DA puede asociarse a comorbilidad inmunoalérgica, sobre todo, del tipo de trastornos como el asma, la rinitis y la conjuntivitis. También se relaciona con una mayor frecuencia de depresión y ansiedad. El tratamiento dependerá de su forma clínica y su gravedad, incluyendo tratamientos tópicos (corticosteroides, tacrólimus, pimecrólimus, crisa borol), tratamientos físicos (fototerapia), tratamientos sistémicos (corticosteroides, ciclosporina, metotrexato, azatioprina, micofenolato de mofetilo), terapias biológicas (dupilumab, tralokinumab, lebrikizumab, nemolizumab) o inhibidores de la cinasa de Jano (JAK; Janus kinase) (baricitinib, upadacitinib, abrocitinib).
- Published
- 2021
22. Biosimilar and interchangeable : inseparable scientific concepts?
- Author
-
Mora Pérez, Fernando de, Balsa, Alejandro, Cornide-Santos, María, Carrascosa, José Manuel, Marsal, Sara, P. Gisbert, Javier, Abad, Miguel-Angel, F. Duarte, Rafael, Wiechmann, Michael, Martínez, Rafael, Universitat Autònoma de Barcelona, and UAM. Departamento de Medicina
- Subjects
medicine.medical_specialty ,Medicina ,Treatment outcome ,interchangeable ,MEDLINE ,Interchangeability ,Drug Substitution ,Interchangeable ,Terminology as Topic ,medicine ,Humans ,Pharmacology (medical) ,Intensive care medicine ,Biosimilar Pharmaceuticals ,Pharmacology ,biosimilarity ,Clinical Trials as Topic ,Biosimilarity ,business.industry ,Biosimilar ,Switch ,Biological ,switch ,Treatment Outcome ,Commentary ,biosimilar ,business ,biological ,interchangeability - Published
- 2019
23. Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study
- Author
-
Descalzo, Miguel Angel, Carretero, Gregorio, Ferrándiz, Carlos, Rivera, Raquel, Daudén, Esteban, Gómez-García, Fran J, de la Cueva, Pablo, Herrera-Ceballos, Enrique, Belinchón, Isabel, López-Estebaranz, José Luis, Alsina, Mercè, Sánchez-Carazo, José Luis, Ferrán, Marta, Baniandrés, Ofelia, Carrascosa, José Manuel, Llamas-Velasco, Mar, Ruiz-Genao, Diana, Herrera-Acosta, Enrique, Muñoz-Santos, Carlos, García-Doval, Ignacio, and Biobadaderm Study Group
- Subjects
0301 basic medicine ,Change over time ,Male ,medicine.medical_specialty ,Time Factors ,Drug-Related Side Effects and Adverse Reactions ,Dermatology ,Systemic therapy ,Cohort Studies ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Psoriasis ,medicine ,Humans ,In patient ,Adverse effect ,Time trends ,business.industry ,Diagnostic test ,Middle Aged ,medicine.disease ,Surgery ,030104 developmental biology ,Female ,business ,Psoriasi -- Tractament ,Cohort study - Published
- 2017
24. Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy
- Author
-
Segaert, Siegfried, Shear, Neil H., Chiricozzi, Andrea, Thaçi, Diamant, Carrascosa, José Manuel, Young, Helen S.., Descamps, Vincent, and Universitat Autònoma de Barcelona
- Subjects
Combination therapy ,medicine.drug_class ,Fixed-dose combination ,Betamethasone dipropionate ,Dermatology ,Review ,Pharmacology ,030207 dermatology & venereal diseases ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Psoriasis ,Vitamin D and neurology ,medicine ,Calcipotriol ,business.industry ,medicine.disease ,chemistry ,Anti-inflammatory ,Plaque psoriasis ,2708 ,030220 oncology & carcinogenesis ,Drug delivery ,Corticosteroid ,Settore MED/35 - MALATTIE CUTANEE E VENEREE ,business ,medicine.drug - Abstract
Altres ajuts:This study was sponsored by LEO Pharma. Article-processing charges were funded by LEO Pharma. Medical writing support was provided by Mai Kurihara, PhD, from Mudskipper Business Limited, funded by LEO Pharma. Fixed-dose combination topical therapy with corticosteroid and vitamin D analog provides effective treatment and possible long-term management of psoriasis. The anti-inflammatory and immunomodulatory effects of corticosteroids and vitamin D analogs in treating psoriasis are well investigated; their complementary effects lead to the disruption of the inflammatory feedback loop underlying psoriasis pathogenesis. Recent preclinical data showed that combination therapy is more effective than monotherapies of the active ingredients in preventing activation of resting pro-inflammatory cells, inducing immunomodulation, reducing inflammatory responses by regulating T cell production, and normalizing keratinocytes. The increased understanding of the mechanism of action of fixed-dose combination therapy from preclinical studies is supported by several clinical studies. As the efficacy of topical therapy is correlated with the skin penetration of the active ingredients, new drug delivery systems have been developed. The fixed-dose combination Cal/BD aerosol foam creates a modified supersaturated formulation when applied to the skin, which is maintained for at least 26 h in the laboratory setting. Clinical studies have demonstrated superior efficacy of fixed-dose combination calcipotriol (Cal) 50 µg/g and betamethasone dipropionate (BD) 0.5 mg/g aerosol foam compared with monotherapies of the active ingredients. Furthermore, Cal/BD aerosol foam has shown significantly improved efficacy compared with more traditional formulations, such as Cal/BD ointment and gel, in other studies. Calcipotriol also mitigates risks associated with betamethasone dipropionate and vice versa, resulting in the favorable safety profile observed with fixed-dose combination treatment. Recent data also suggest that fixed-dose combination treatment could provide long-term management of psoriasis, although further clinical investigations are needed. Overall, these data support the value of fixed-dose combination therapy of corticosteroid and vitamin D analog and highlight the added potential of innovative drug delivery for the treatment of psoriasis. LEO Pharma.
- Published
- 2017
25. Presentación
- Author
-
Carrascosa, José Manuel, primary
- Published
- 2018
- Full Text
- View/download PDF
26. Genetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis
- Author
-
Consuegra-Fernández, Marta, primary, Julià, Marc, additional, Martínez-Florensa, Mario, additional, Aranda, Fernando, additional, Català, Cristina, additional, Armiger-Borràs, Noelia, additional, Arias, María-Teresa, additional, Santiago, Francisca, additional, Guilabert, Antonio, additional, Esteve, Anna, additional, Muñoz, Carlos, additional, Ferrándiz, Carlos, additional, Carrascosa, José- Manuel, additional, Pedrosa, Edurne, additional, Romaní, Jorge, additional, Alsina, Mercè, additional, Mascaró-Galy, José- Manuel, additional, and Lozano, Francisco, additional
- Published
- 2017
- Full Text
- View/download PDF
27. Immune-mediated inflammatory diseases differently affect IGRAs’ accuracy for latent tuberculosis infection diagnosis in clinical practice
- Author
-
Latorre, Irene, primary, Mínguez, Sonia, additional, Carrascosa, José-Manuel, additional, Naves, Juan, additional, Villar-Hernández, Raquel, additional, Muriel, Beatriz, additional, Prat, Cristina, additional, García-García, Esther, additional, Casas, Irma, additional, Domènech, Eugeni, additional, Ferrándiz, Carlos, additional, Mateo, Lourdes, additional, and Domínguez, Jose, additional
- Published
- 2017
- Full Text
- View/download PDF
28. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry
- Author
-
Dávila-Seijo, Paula, primary, Dauden, Esteban, additional, Descalzo, M.A., additional, Carretero, Gregorio, additional, Carrascosa, José-Manuel, additional, Vanaclocha, Francisco, additional, Gómez-García, Francisco-José, additional, De la Cueva-Dobao, Pablo, additional, Herrera-Ceballos, Enrique, additional, Belinchón, Isabel, additional, López-Estebaranz, José-Luis, additional, Alsina, Merce, additional, Sánchez-Carazo, José-Luis, additional, Ferrán, Marta, additional, Torrado, Rosa, additional, Ferrandiz, Carlos, additional, Rivera, Raquel, additional, Llamas, Mar, additional, Jiménez-Puya, Rafael, additional, García-Doval, Ignacio, additional, Pérez Zafrilla, Beatriz, additional, Muñoz-Santos, Carlos, additional, Mendiola-Fernández, Victoria, additional, Sánchez Roldán, Cristina, additional, Ruiz-Genao, Diana, additional, Echeverría, Begoña, additional, and Galiano Mejías, Sagrario, additional
- Published
- 2017
- Full Text
- View/download PDF
29. CCL4L Polymorphisms and CCL4/CCL4L Serum Levels Are Associated with Psoriasis Severity
- Author
-
Pedrosa, Edurne, primary, Carretero-Iglesia, Laura, additional, Boada, Aram, additional, Colobran, Roger, additional, Faner, Rosa, additional, Pujol-Autonell, Irma, additional, Palou, Eduard, additional, Esteve, Anna, additional, Pujol-Borrell, Ricardo, additional, Ferrándiz, Carlos, additional, Juan, Manel, additional, and Carrascosa, José-Manuel, additional
- Published
- 2011
- Full Text
- View/download PDF
30. Presentación.
- Author
-
Carrascosa, José Manuel
- Published
- 2018
- Full Text
- View/download PDF
31. Actas Dermo-Sifiliográficas 1909-2009
- Author
-
Daudén, Esteban, Longo, Isabel, de Argila, Diego, and Carrascosa, José Manuel
- Published
- 2009
- Full Text
- View/download PDF
32. Efectividad y seguridad de los nuevos tratamientos para la psoriasis moderada- grave en la práctica clínica real
- Author
-
del Alcázar Viladomiu, Elena and Carrascosa, José Manuel
- Subjects
Psoriasi ,Treatments ,616.5 ,Psoriasis ,Pràctica clínica ,Práctica clínica ,Clinical practice ,Ciències de la Salut ,Tractaments ,Tratamientos - Abstract
Les dades d'efectivitat i seguretat d'un fàrmac a la vida real es consideren essencials per a ponderar els resultats dels assaigs pivotals per a la presa de decisions dels clínics. L'objectiu va ser el de avaluar l'efectivitat i seguretat de nous fàrmacs per al tractament de la psoriasi moderada-greu. Es van realitzar tres estudis multicèntrics, observacionals i retrospectius. El primer d'ells va avaluar l'efectivitat i seguretat d'ustekinumab 90mg en una cohort de pacients amb un pes ≤100kg a les 24 setmanes. Els altres dos van avaluar l'efectivitat i seguretat d'apremilast a les 52 setmanes i de guselkumab a les 24 setmanes. En el primer treball es van incloure 74 pacients. El PASI basal (DE) mig va ser de 7.9 (4.8), 3.3 (3.5) a la setmana 16 i 2.2 (2.4) a la setmana 24. En aquest punt temporal, el 69.7% dels pacients van aconseguir un PASI ≤3, el 56.1% el PASI 75 i el 31.8% el PASI 90. No es van observar diferències significatives segons l' IMC de sobrepès o obesitat (p=0.995). En el grup de pacients que havia estat tractat prèviament amb UST 45 mg amb resposta insuficient, el PASI mig (DE) va ser de 2.7 (2.6) a la setmana 24 i el 63% va aconseguir el PASI ≤3. Respecte a la seguretat, no es van informar esdeveniments adversos (EA) greus. La sèrie de guselkumab va incloure 343 pacients. A les 24 setmanes, el PASI mig va disminuir de 11.1 (7.3) a 1.7(2.8), un 85.9% de pacients va aconseguir el PASI ≤4 i un 77.9% el PASI ≤2. En paràmetres de milloria relativa, un 59.4% dels pacients van aconseguir el PASI 90 i el 49.0% el PASI 100. A l'anàlisi multivariant es va observar que un IMC ≥30 (OR 0.44;95% IC [0.22-0.88]) i una major exposició a teràpia biològica prèvia (OR 0.69; 95% IC [0.56-0.84]) disminueixen la probabilitat d'aconseguir el PASI ≤2 a les 24 setmanes: La presencia d'EA va ser infreqüent (9,9%), sent motiu de suspensió només en 9 pacients (2.6%). La cohort d' apremilast va incloure 292 pacients amb psoriasi en placa i 85 amb psoriasi palmoplantar. El PASI mig basal dels pacients amb psoriasi en placa va ser de 10.7 (7.0), disminuint a 3.0 (4.2) a les 52 setmanes. Als 12 mesos, un 73.6% dels pacients van aconseguir un PASI ≤3. En paràmetres de PASI relatiu, un 49.7 % va aconseguir el PASI 75 i un 26.5% el PASI 90 a la setmana 52. En el grup de psoriasi palmoplantar, el physician global assessment (PPPGA) mig inicial va ser de 4.2 (5.2) i es va reduir a 1.3 (1.3) a les 52 setmanes. La supervivència del fàrmac va ser del 54.9% als 12 mesos. Els principals motius de discontinuació van ser la pèrdua d'eficàcia (23.9%), seguida de la presencia d'EA (15.9%). A la nostra sèrie el 47% dels pacients va presentar algun EA, sent els més freqüents els de tipus gastrointestinal. Els treballs presentats en aquesta tesi representen un reflex encertat, contemporani i en temps real dels resultats de la revolució terapèutica en psoriasi i han estat les series més nombroses per a cadascun dels fàrmacs. Els estudis reflecteixen, per un costat, que l'objectiu terapèutic es diferent a la pràctica clínica dels assaigs clínics, destacant el PASI absolut com a paràmetre d'èxit terapèutic enfront a la millora relativa dels assaigs pivotals i, per un altre costat, que el perfil de pacient de la pràctica clínica diària real es més complex. Respecte a la seguretat dels fàrmacs, la pràctica clínica també reflexa la freqüència dels EA i la tolerabilitat dels diferents tractaments. Los datos de efectividad y seguridad de un fármaco en vida real se consideran esenciales para ponderar los resultados de los ensayos pivotales para la toma de decisiones de los clínicos. El objetivo fue evaluar la efectividad y seguridad de nuevos fármacos para el tratamiento de la psoriasis moderada-grave. Se realizaron tres estudios multicéntricos, observacionales y retrospectivos. El primero evaluó la efectividad y seguridad de ustekinumab (UST) 90mg en una cohorte de pacientes con un peso ≤100kg a las 24 semanas. Los otros dos evaluaron la efectividad y seguridad de apremilast a las 52 semanas y de guselkumab a las 24 semanas. En el primer trabajo se incluyeron 74 pacientes. El PASI basal (DE) medio fue de 7.9 (4.8), 3.3 (3.5) en la semana 16 y 2.2 (2.4) en la semana 24. En este punto temporal, el 69.7% de los pacientes alcanzaron un PASI ≤3, el 56.1% el PASI 75 y el 31.8% el PASI 90. No se observaron diferencias significativas según el IMC de sobrepeso u obesidad (p=0.995). En el grupo de pacientes que había sido tratado previamente con UST 45 mg con respuesta insuficiente, el PASI medio (DE) fue de 2.7 (2.6) en la semana 24 y el 63% alcanzó el PASI ≤3. Respecto a la seguridad, no se informaron acontecimientos adversos (AA) graves. La serie de guselkumab incluyó 343 pacientes. A las 24 semanas, el PASI medio descendió de 11.1 (7.3) a 1.7(2.8), un 85.9% de pacientes alcanzó el PASI ≤4 y un 77.9% el PASI ≤2. En términos de mejoría relativa, un 59.4% de los pacientes alcanzaron el PASI 90 y el 49.0% el PASI 100. En el análisis multivariante se observó que un IMC ≥30 (OR 0.44;95% IC [0.22-0.88]) y una mayor exposición a terapia biológica previa (OR 0.69; 95% IC [0.56-0.84]) disminuyen la probabilidad de alcanzar PASI ≤2 a las 24 semanas:. La presencia de AA fue infrecuente (9,9%), siendo motivo de suspensión únicamente en 9 pacientes (2.6%). La cohorte de apremilast incluyó un total de 292 pacientes con psoriasis en placa y 85 con psoriasis palmoplantar. El PASI medio basal de los pacientes con psoriasis en placa fue de 10.7 (7.0), descendiendo 3.0 (4.2) a las 52 semanas. A los 12 meses, un 73.6% de los pacientes alcanzaron un PASI ≤3. En términos de PASI relativo, un 49.7 % consiguió el PASI 75 y un 26.5% el PASI 90 a la semana 52. En el grupo de psoriasis palmoplantar, el physician global assessment (PPPGA) medio inicial fue de 4.2 (5.2) y se redujo a 1.3 (1.3) a las 52 semanas. La supervivencia del fármaco fue del 54.9% a los 12 meses. Los principales motivos de discontinuación fueron la pérdida de eficacia (23.9%), seguida de la presencia de AA (15.9%). En nuestra serie el 47% de los pacientes presentó algún AA, siendo los más frecuentes los de tipo gastrointestinal. Los trabajos presentados en esta tesis representan un reflejo certero, contemporáneo y en tiempo real de los resultados de la revolución terapéutica en psoriasis y han sido, las series más numerosas para cada uno de los fármacos. Los estudios reflejan, por un lado, que el objetivo de eficacia en la práctica clínica es distinto al de los ECA, destacando el PASI absoluto como parámetro de éxito terapéutico frente a la mejoría relativa de los ensayos pivotales y, por otro lado, que el perfil de paciente de la práctica clínica real es más complejo. Respecto a la seguridad de los fármacos, la práctica clínica también refleja la frecuencia de los AA y la tolerabilidad de los distintos tratamientos. Physicians must evaluate the results of pivotal trials together with real-world data on effectiveness and safety when making clinical decisions. The objective was to evaluate the safety and effectiveness of new drugs for the treatment of moderate to severe psoriasis in clinical practice. The research comprised three retrospective, observational, multicentre studies. The first evaluated the effectiveness and safety of ustekinumab 90 mg at week 24 in a group of patients weighing ≤100kg. The other two evaluated the effectiveness and safety of apremilast at 52 weeks and guselkumab at 24 weeks. The first study analysed data from 74 patients. Mean (SD) score on the Psoriasis Area and Severity Index (PASI) was 7.9 (4.8) at baseline, 3.3 (3.5) at week 16, and 2.2 (2.4) at week 24. By week 24, 69.7% of the patients had an absolute PASI score under 3, 56.1% presented a PASI 75 response (at least 75% reduction from baseline), and 31.8% a PASI 90 response. A body mass index corresponding to overweight or obesity was not associated with any significant differences (p = 0.995). In the group of patients who had presented an inadequate response to prior treatment with UST 45 mg, the mean PASI was 2.7 (2.6) at week 24, and 63% of the patients had a PASI score under 3. Analysis of the safety data did not reveal any serious adverse events (AE). The study of guselkumab analysed data from 343 patients. By week 24, the mean PASI score had fallen from 11.1 (7.3) to 1.7 (2.8); 85.9% of patients had a PASI of 4 or less and 77.9% a PASI of 2 or less. In terms of relative improvement, 59.4% of the patients studied achieved a PASI 90 response and 49.0% a PASI 100 response. On multivariate analysis, a BMI of 30 or less (OR, 0.44; 95% CI, 0.22-0.88) and greater prior exposure to biologic therapy (OR, 0.69; 95% CI, 0.56-0.84) reduced the moderate probability of the patient achieving a PASI score of 2 or less at 24 weeks. AE were rare (9.9%) and had led to withdrawal of treatment in only 9 patients (2.6%) The apremilast cohort included a total of 292 patients with plaque psoriasis and 85 with palmoplantar psoriasis. In the patients with plaque psoriasis, mean PASI was 10.7 (7.0) at baseline decreasing to 3.0 (4.2) at 52 weeks. After 12 months of treatment, 73.6% of the patients had a PASI score of 3 or less. In terms of relative improvement, 49.7% achieved PASI 75 and 26.5% PASI 90 at week 52. In the group with palmoplantar psoriasis, the mean physician global assessment (PGA) score fell from 4.2 (5.2) at baseline to 1.3 (1.3) at week 52. Drug survival was 54.9% at 12 months. The main reasons for discontinuing treatment were loss of efficacy (23.9%) and AE (15.9%). In this series, 47% of the patients experienced AE, with the most common being gastrointestinal effects. The studies reported in this thesis are an accurate, contemporary, and real-time reflection of the results of the revolution in the treatment of psoriasis and represent the largest published series for each of the drugs studied. These studies highlight two fundamental differences between pivotal trials and real-world practice. The first is the use of endpoints reflecting relative clinical improvement in RCTs as against the use of the absolute PASI score to measure treatment outcomes in clinical practice. The second difference is the greater complexity of the patient profile in real-world clinical practice. With respect to safety, analysis of the data from routine clinical practice evidences the frequency of AE and the tolerability of the different treatments.
- Published
- 2022
33. Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study
- Author
-
Tiago Torres, Luis Puig, Ron Vender, Jensen Yeung, José-Manuel Carrascosa, Stefano Piaserico, Paolo Gisondi, Charles Lynde, Paulo Ferreira, Pedro Mendes Bastos, Esteban Dauden, Luiz Leite, Joana Valerio, Elena del Alcázar-Viladomiu, Eva Vilarrasa Rull, Mar Llamas-Velasco, Federico Pirro, Francesco Messina, Manfredo Bruni, Gaetano Licata, Federica Ricceri, Alessia Nidegger, Jan Hugo, Asfandyar Mufti, Athina-Ioanna Daponte, Laetitia Teixeira, Anna Balato, Marco Romanelli, Francesca Prignano, Spyridon Gkalpakiotis, Curdin Conrad, Elizabeth Lazaridou, Natalia Rompoti, Marina Papoutsaki, Miguel Nogueira, Andrea Chiricozzi, Torres, Tiago, Puig, Lui, Vender, Ron, Yeung, Jensen, Carrascosa, José-Manuel, Piaserico, Stefano, Gisondi, Paolo, Lynde, Charle, Ferreira, Paulo, Bastos, Pedro Mende, Dauden, Esteban, Leite, Luiz, Valerio, Joana, Del Alcázar-Viladomiu, Elena, Rull, Eva Vilarrasa, Llamas-Velasco, Mar, Pirro, Federico, Messina, Francesco, Bruni, Manfredo, Licata, Gaetano, Ricceri, Federica, Nidegger, Alessia, Hugo, Jan, Mufti, Asfandyar, Daponte, Athina-Ioanna, Teixeira, Laetitia, Balato, Anna, Romanelli, Marco, Prignano, Francesca, Gkalpakiotis, Spyridon, Conrad, Curdin, Lazaridou, Elizabeth, Rompoti, Natalia, Papoutsaki, Marina, Nogueira, Miguel, and Chiricozzi, Andrea
- Subjects
Adult ,Treatment Outcome ,drug survival ,Interleukin-17 ,Humans ,Interleukin Inhibitors ,Psoriasis ,Dermatology ,General Medicine ,Settore MED/35 - MALATTIE CUTANEE E VENEREE ,Interleukin-23 ,Severity of Illness Index ,Retrospective Studies - Abstract
Background Drug survival, defined as the length of time from initiation to discontinuation of a given therapy, allows comparisons between drugs, helps to predict patient's likelihood of remaining on a specific treatment, and achieving the best decision for each patient in daily clinical practice. Objective The aim of this study was to provide data on drug survival of secukinumab, ixekizumab, brodalumab, guselkumab, tildrakizumab, and risankizumab in a large international cohort, and to identify clinical predictors that might have an impact on the drug survival of these drugs. Methods This was a retrospective, multicentric, multi-country study that provides data of adult patients with moderate to severe psoriasis who started treatment with an interleukin (IL)-17 or IL-23 inhibitor between 1 February 2015 and 31 October 2021. Data were collected from 19 distinct hospital and non-hospital-based dermatology centers from Canada, Czech Republic, Italy, Greece, Portugal, Spain, and Switzerland. Kaplan-Meier estimator and proportional hazard Cox regression models were used for drug survival analysis. Results A total of 4866 treatment courses (4178 patients)-overall time of exposure of 9500 patient-years-were included in this study, with 3164 corresponding to an IL-17 inhibitor (secukinumab, ixekizumab, brodalumab) and 1702 corresponding to an IL-23 inhibitor (guselkumab, risankizumab, tildrakizumab). IL-23 inhibitors had the highest drug survival rates during the entire study period. After 24 months of treatment, the cumulative probabilities of drug survival were 0.92 (95% confidence interval [CI] 0.89-0.95) for risankizumab, 0.90 (95% CI 0.88-0.92) for guselkumab, 0.80 (95% CI 0.76-0.84) for brodalumab, 0.79 (95% CI 0.76-0.82) for ixekizumab, and 0.75 (95% CI 0.73-0.77) for secukinumab. At 36 months, only guselkumab [0.88 (95% CI 0.85-0.91)], ixekizumab [0.73 (95% CI 0.70-0.76)], and secukinumab [0.67 (95% CI 0.65-0.70)] had more than 40 patients at risk of drug discontinuation. Only two drugs had more than 40 patients at risk of drug discontinuation at 48 months, with ixekizumab demonstrating to have a higher cumulative probability of drug survival [0.71 (95% CI 0.68-0.75)] when compared with secukinumab [0.63 (95% CI 0.60-0.66)]. Secondary failure was the main cause for drug discontinuation. According to the final multivariable model, patients receiving risankizumab, guselkumab, and ixekizumab were significantly less likely to discontinue treatment than those receiving secukinumab. Previous exposure to biologic agents, absent family history of psoriasis, higher baseline body mass index (BMI), and higher baseline Psoriasis Area and Severity Index (PASI) were identified as predictors of drug discontinuation. Conclusion The cumulative probability of drug survival of both IL-17 and IL-23 inhibitors was higher than 75% at 24 months, with risankizumab and guselkumab demonstrating to have overall cumulative probabilities >= 90%. Biological agent chosen, prior exposure to biologic agents, higher baseline BMI and PASI values, and absence of family history of psoriasis were identified as predictors for drug discontinuation. Risankizumab, guselkumab, and ixekizumab were less likely to be discontinued than secukinumab.
- Published
- 2022
34. Lupus eritematoso túmido. Estudio clínico, microscópico y fotobiológico
- Author
-
Bielsa Marsol, Ma. Isabel and Carrascosa, José Manuel
- Subjects
Lupus erimatós - Published
- 2021
35. Diagnóstico de la infección tuberculosa mediante IGRAs en pacientes con psoriasis
- Author
-
Carrascosa, José Manuel
- Subjects
Tuberculosi, Psoriasi, Dermatologia - Published
- 2021
36. Perfil clínico y curso evolutivo de los pacientes tratados con efalizumab tras la suspensión de su autorización por la EMEA. Estudio observacional y multicéntrico
- Author
-
Carrascosa, José Manuel and Bielsa Marsol, Ma. Isabel
- Subjects
Psoriasi - Published
- 2021
37. Lupus eritematoso túmido. Estudio clínico, microscópico y fotobiológico
- Author
-
Rodríguez Caruncho, Clara, Universitat Autònoma de Barcelona. Departament de Medicina, Universitat Autònoma de Barcelona. Facultat de Medicina, Bielsa Marsol, Ma. Isabel, and Carrascosa, José Manuel
- Subjects
Lupus erimatós - Abstract
Hem realitzat un estudi retrospectiu de les característiques de 25 pacients amb lupus eritematós túmid (LET) i hem dut a terme un estudi fotobiológic en 9 pacients. Resultats: tots els pacients presentaren les lesions característiques de LET. Només un 20% associaren ANA positius i tan sols un pacient anti Ro positius. Cap pacient presentà complicacions sistèmiques. El 40% de les biòpsies mostraren alteracions epidérmiques lleus, sent el més freqüent la vaquolització de la basal. Estudi fotobiológic: fou positiu en el 55'5% dels pacients, amb un 80% de lesions provocades per UVB. Conclusions: El LET és una variant de LEC amb unes característiques clíniques i evolutives particulars. Microscòpicament, la presència d'alteracions epidérmiques lleus és molt més habitual del que alguns treballs reflecteixen. La fotoprovocació fou positiva en un percentatge significatiu de casos, predominantment dins de l'espectre UVB. Hemos realizado un estudio retrospectivo revisando las características de 25 pacientes con lupus eritematoso túmido (LET) y hemos llevado a cabo un estudio fotobiológico en 9 pacientes. Resultados: todos los pacientes presentaron las lesiones características de LET. Sólo un 20% presentó ANA positivos y tan sólo un paciente anti Ro positivos. Ningún paciente presentó complicaciones sistémicas. El 40% de las biopsias mostraron alteraciones epidérmicas leves, el más frecuente vacuolización focal de la basal. Estudio fotobiológico: fue positivo en el 55'5% de los pacientes, con un 80% de lesiones por UVB. Conclusiones: El LET constituye una variante de LEC con unas características clínicas y evolutivas particulares. Microscópicamente, la presencia de alteraciones epidérmicas leves es mucho más habitual de lo que algunos trabajos reflejan. La fotoprovocación fue positiva en un porcentaje significativo de casos, de forma predominante dentro del espectro UVB.
- Published
- 2021
38. Diagnóstico de la infección tuberculosa mediante IGRAs en pacientes con psoriasis
- Author
-
Vilavella Rius, Marta, Universitat Autònoma de Barcelona. Departament de Medicina, Universitat Autònoma de Barcelona. Facultat de Medicina, and Carrascosa, José Manuel
- Subjects
Tuberculosi, Psoriasi, Dermatologia - Abstract
El úso de anti-TNF-α se ha asociado a reactivación de infección tuberculosa latente (ITL). Los IGRAs son pruebas in vitro más sensibles y mas específicas que la prueba de la prueba de la tuberculina (PT). El objetivo de este trabajo es el de contrastar la correlación entre los resultados de las técnicas in vitro y la PT. Analizamos 103 pacientes con psoriasis en tratamiento sistémico. Los resultados de nuestra serie permiten sugerir una mayor sensibilidad y especificidad de los IGRAs en la detección de ITL respecto a la PT, de forma independiente al estado de inmunosupresión y al fármaco empleado, con alta concordancia entre los IGRAs. L'ús d'anti-TNF- α s'ha associat a reactivació de la infecció tuberculosa latent (ITL). Els IGRAs són proves in vitro més sensibles i més específiques que la prova de la tuberculina (PT). L'objectiu d'aquest treball és el de contrastar la correlació entre els resultats de les tècniques in vitro i la PT. Vam analitzar 103 pacients amb psoriasis en tractament sistèmic. Els resultats de la nostra sèrie permeten suggerir una major sensibilitat i especificitat dels IGRAs en la detecció d'ITL respecte la PT, de manera independent a l'estat d'immunosupressió i al fàrmac emprat, amb alta concordància entre els IGRAs.
- Published
- 2021
39. Perfil clínico y curso evolutivo de los pacientes tratados con efalizumab tras la suspensión de su autorización por la EMEA. Estudio observacional y multicéntrico
- Author
-
Morell Franco, Laia, Universitat Autònoma de Barcelona. Departament de Medicina, Universitat Autònoma de Barcelona. Facultat de Medicina, Carrascosa, José Manuel, and Bielsa Marsol, Ma. Isabel
- Subjects
Psoriasi - Abstract
L'objectiu de l'estudi fou avaluar el curs de la psoriasi després de la suspensió forçosa de l'efalizumab en un grup de 147 pacients procedents de 12 hospitals. Es recollí informació referida al perfil epidemiològic, al curs de la dermatosi durant el tractament i a l'evolució després de la suspensió. Durant el tractament, un 4% dels pacients fou diagnosticat d'exacerbació inflamatòria. Bona part dels pacients van ser classificats com a bons responedors, grup a priori de millor pronòstic. Tot i així, després de la suspensió, un 30% van desenvolupar rebot. La probabilitat de rebot fou independent de qualsevol dels paràmetres avaluats. El objetivo del estudio fue evaluar el curso de la psoriasis tras la suspensión forzosa de efalizumab en un grupo de 147 pacientes procedentes de 12 hospitales. Se recogió información referida al perfil epidemiológico, al curso de la dermatosis durante el tratamiento y a su evolución al suspenderlo. Durante el tratamiento, un 4% de los pacientes fue diagnosticado de exacerbación inflamatoria. La mayor parte de los pacientes pudieron ser clasificados como buenos respondedores, grupo a priori de mejor pronóstico. Sin embargo, un 30% presentaron rebote tras la suspensión. La probabilidad de rebote fue independiente de los distintos parámetros evaluados.
- Published
- 2021
40. Challenges for New Adopters in Pre-Surgical Margin Assessment by Handheld Reflectance Confocal Microscope of Basal Cell Carcinoma; A Prospective Single-center Study.
- Author
-
Richarz NA, Boada A, Jaka A, Bassas J, Ferrándiz C, Carrascosa JM, and Yélamos O
- Abstract
Introduction: In vivo reflectance confocal microscopy (RCM) is a useful tool for assessing pre-surgical skin tumor margins when performed by a skilled, experienced user. The technique, however, poses significant challenges to novice users, particularly when a handheld RCM (HRCM) device is used., Objectives: To evaluate the performance of an HRCM device operated by a novice user to delineate basal cell carcinoma (BCC) margins before Mohs micrographic surgery (MMS)., Methods: Prospective study of 17 consecutive patients with a BCC in a high-risk facial area (the H zone) in whom tumor margins were assessed by HRCM and dermoscopy before MMS. Predicted surgical defect areas (cm
2 ) were calculated using standardized photographic digital documentation and compared to final defect areas after staged excision., Results: No significant differences were observed between median HRCM-predicted and observed surgical defect areas (2.95 cm2 [range: 0.83-17.52] versus 2.52 cm2 [range 0.71-14.42]; P = 0.586). Dermoscopy, by contrast, produced significantly underestimated values (median area of 1.34 cm2 [0.41-4.64] versus 2.52 cm2 [range 0.71-14.42]; P < 0.001). Confounders leading to poor agreement between predicted and observed areas were previous treatment (N = 5), a purely infiltrative subtype (N = 1), and abundant sebaceous hyperplasia (N = 1)., Conclusions: Even in the hands of a novice user, HRCM is more accurate than dermoscopy for delineating lateral BCCs margins in high-risk areas and performs well at predicting final surgical defects., Competing Interests: Competing interests: None., (©2022 Richarz et al.)- Published
- 2022
- Full Text
- View/download PDF
41. [Introduction].
- Author
-
Carrascosa JM
- Subjects
- Adolescent, Adult, Humans, Consensus Development Conferences as Topic, Dermatitis, Atopic diagnosis, Dermatitis, Atopic therapy, Practice Guidelines as Topic
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.